Patents by Inventor Camille Chypre

Camille Chypre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to detect prostate cancer in a sample
    Patent number: 11104958
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 31, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
  • Method to Detect Prostate Cancer in a Sample
    Publication number: 20180363064
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 20, 2018
    Applicant: Gen-Probe Incorporated
    Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
  • Method to detect prostate cancer in a sample
    Patent number: 10006092
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: June 26, 2018
    Assignee: Gen-Probe Incorporated
    Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20180171416
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: January 17, 2018
    Publication date: June 21, 2018
    Applicant: Gen-Probe Incorporated
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
    Patent number: 9909189
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: March 6, 2018
    Assignee: Gen-Probe Incorporated
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • METHOD TO DETECT PROSTATE CANCER IN A SAMPLE
    Publication number: 20160281174
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Application
    Filed: April 7, 2016
    Publication date: September 29, 2016
    Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20160208336
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: November 17, 2015
    Publication date: July 21, 2016
    Applicant: Gen-Probe Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20140087384
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 27, 2014
    Applicant: DiagnoCure Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
    Patent number: 8618276
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: December 31, 2013
    Assignee: DiagnoCure Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • METHOD TO DETECT PROSTATE CANCER IN A SAMPLE
    Publication number: 20130344487
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: DiagnoCure Inc.
    Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
  • Method to detect prostate cancer in a sample
    Patent number: 8546551
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 1, 2013
    Assignee: DiagnoCure Inc.
    Inventors: Yves Fradet, Camille Chypre, Lyson Piché, Geneviève Garon
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20120315634
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: August 2, 2012
    Publication date: December 13, 2012
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • METHOD TO DETECT PROSTATE CANCER IN A SAMPLE
    Publication number: 20120309001
    Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
    Type: Application
    Filed: May 14, 2012
    Publication date: December 6, 2012
    Inventors: Yves Fradet, Camille Chypre, Lyson Piché, Geneviève Garon
  • Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
    Patent number: 8241848
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: August 14, 2012
    Assignee: DiagnoCure Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • Method to detect prostate cancer in a sample
    Patent number: 8192931
    Abstract: The present invention relates to prostate cancer. More specifically, the present invention relates to a method to detect prostate cancer in a patient sample by detecting the RNA encoded by the gene PCA3. More particularly the present invention relates to a method for determining a predisposition, or presence of prostate cancer in a patient comprising: (a) contacting a biological sample of a patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting in the biological sample an amount of PCA3 and second prostate specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: June 5, 2012
    Assignee: DiagnoCure Inc.
    Inventors: Yves Fradet, Camille Chypre, Lyson Piché, Geneviéve Garon
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20110212449
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: April 5, 2011
    Publication date: September 1, 2011
    Inventors: Ursula BUSSE, Camille CHYPRE, Yves FRADET
  • METHOD TO DETECT PROSTATE CANCER IN A SAMPLE
    Publication number: 20110165573
    Abstract: The present invention relates to prostate cancer. More specifically, the present invention relates to a method to detect prostate cancer in a patient sample by detecting the RNA encoded by the gene PCA3. More particularly the present invention relates to a method for determining a predisposition, or presence of prostate cancer in a patient comprising: (a) contacting a biological sample of a patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting in the biological sample an amount of PCA3 and second prostate specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample.
    Type: Application
    Filed: July 10, 2009
    Publication date: July 7, 2011
    Inventors: Yves FRADET, Camille Chypre, Lyson Piche, Genevieve Garon
  • Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
    Patent number: 7927806
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: April 19, 2011
    Assignee: Diagnocure Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet
  • DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
    Publication number: 20100129824
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Application
    Filed: December 11, 2009
    Publication date: May 27, 2010
    Inventors: URSULA BUSSE, CAMILLE CHYPRE, YVES FRADET
  • PCA3 messenger RNA species in benign and malignant prostate tissues
    Patent number: 7655408
    Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: February 2, 2010
    Assignee: Diagnocure Inc.
    Inventors: Ursula Busse, Camille Chypre, Yves Fradet